Blue Earth Diagnostics Limited
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$27.3M
Doctors Paid
7,827
Transactions
25,616
2024 Total
$2.7M
Payment Breakdown by Category
Research$23.8M (87.2%)
Consulting$2.3M (8.2%)
Food & Beverage$590,630 (2.2%)
Travel$137,657 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.8M | 2,132 | 87.2% |
| Consulting Fee | $2.3M | 513 | 8.2% |
| Food and Beverage | $590,630 | 22,302 | 2.2% |
| Honoraria | $267,934 | 139 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $186,638 | 104 | 0.7% |
| Travel and Lodging | $137,657 | 232 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $27,900 | 13 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $18,550 | 20 | 0.1% |
| Education | $5,641 | 159 | 0.0% |
| Grant | $3,700 | 2 | 0.0% |
Payments by Type
Research
$23.8M
2,131 transactions
General
$3.5M
23,484 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy. | $5.5M | 0 | 203 |
| A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer | $3.5M | 0 | 193 |
| The Impact of 18F Fluciclovine FACBC PETCT Positron Emission Computed Tomography on Management of Patients With Rising PSA Prostate-specific Antigen After Initial Prostate Cancer Treatment | $1.6M | 0 | 232 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy | $1.5M | 0 | 144 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy (the Protocol). | $1.3M | 0 | 76 |
| Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT) | $716,059 | 0 | 52 |
| Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | $550,199 | 0 | 103 |
| An Open-label multicentre Phase 1/2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of 177Lu-rhPSMA-10.1 in Men with Castrate Resistant Prostate Cancer | $546,855 | 0 | 23 |
| Retrospective Observational Study Investigating Fluciclovine 18F FACBC | $501,304 | 0 | 6 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy | $452,534 | 0 | 46 |
| Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | $434,217 | 0 | 42 |
| Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE) | $390,678 | 0 | 48 |
| Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | $377,337 | 0 | 45 |
| An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy as it is amended time to time and approved by the IRB (the Protocol) | $306,499 | 0 | 35 |
| Utility of FDG-PET Scanning in Prostate Cancer Patients with Biochemical Recurrence | $282,500 | 0 | 2 |
| PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy | $255,184 | 0 | 27 |
| Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy | $240,265 | 0 | 38 |
| To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression vs pseudoprogression. To determine a multidimensional signature using 18F-fluciclovine PET, MRI, and plasma cfDNA that accurately differentiates tumor progression from pseudoprogression in post-chemoradiation GBM. | $238,657 | 0 | 31 |
| rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | $209,026 | 0 | 25 |
| Prospective Comparison of Pelvic CT or MRI Plus Bone Scanning With 99mTc-MDP Bone Scan and/or 18F-NaF PET/CT to 18F- Fluciclovine PET/CT in VA Prostate Cancer Patients With BCR. | $196,875 | 0 | 33 |
| Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | $196,388 | 0 | 17 |
| Prospective Comparison of Pelvic CT or MRI Plus Bone Scanning With 99mTc-MDP Bone Scan andor 18F-NaF PETCT to 18F- Fluciclovine PETCT in VA Prostate Cancer Patients With BCR. | $174,180 | 0 | 37 |
| Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy | $162,905 | 0 | 24 |
| CLINICAL UTILITY OFAXUMINPET/MRI IMAGING TWO YEARS FOLLOWINGFOCAL CRYO-ABLATION(FCA) OF PROSTATE CANCER | $161,470 | 0 | 26 |
| PSMA-PET during therapy for metastatic hormone-sensitive prostate cancer | $160,099 | 0 | 11 |
| The Effect of Androgen Deprivation Therapy on rh-F18 PSMA PET Scan Sensitivity | $159,503 | 0 | 23 |
| Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. | $144,800 | 0 | 27 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis | $142,861 | 0 | 18 |
| Fluciclovine(FACBC)PET/CT Site-Directed TherapyforTreatmentofProstate Cancer | $133,333 | 0 | 4 |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis (CONCORDANT) | $127,500 | 0 | 21 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Jian Qin Yu, M.d, M.D | Specialist | Philadelphia, PA | $4,911 | $0 |
| Shawn Carter, Md, MD | Nuclear Medicine | Sarasota, FL | $4,896 | $0 |
| Dr. David Meredith, M.d., Ph.d, M.D., PH.D | Anatomic Pathology | Boston, MA | $4,800 | $0 |
| Dr. Przemyslaw Twardowski, Md, MD | Internal Medicine | Santa Monica, CA | $4,796 | $0 |
| Apoorva Vashi, Md, MD | Urology | Jacksonville, FL | $4,744 | $0 |
| Dr. Daniel Margolis, M.d, M.D | Diagnostic Radiology | New York, NY | $4,723 | $0 |
| Dr. Emmanuel Antonarakis, M.d, M.D | Medical Oncology | Minneapolis, MN | $4,500 | $0 |
| Marcus Ware, M.d, M.D | Neurological Surgery | New Orleans, LA | $4,429 | $0 |
| Dr. Kent Friedman, M.d, M.D | Nuclear Radiology | New York, NY | $4,422 | $0 |
| Jeremie Calais, Md, MD | Nuclear Imaging & Therapy | Los Angeles, CA | $4,350 | $0 |
| Rathan Subramaniam, Md, Phd, Mph, MD, PHD, MPH | Nuclear Radiology | Dallas, TX | $4,281 | $0 |
| Mary-Ellen Taplin, Md, MD | Medical Oncology | Boston, MA | $4,250 | $0 |
| Jonathan Levy, Md, MD | Diagnostic Radiology | Scottsdale, AZ | $4,222 | $0 |
| Dr. Paul Nguyen, Md, MD | Radiation Oncology | Boston, MA | $4,195 | $0 |
| Seyed Nabavizadeh, Md, MD | Diagnostic Radiology | Philadelphia, PA | $4,185 | $0 |
| Daniel Appelbaum | Nuclear Radiology | Chicago, IL | $4,100 | $0 |
| Minesh Mehta, Md, MD | Radiation Oncology | Miami, FL | $4,038 | $0 |
| Dr. Alton Sartor, M.d, M.D | Medical Oncology | Rochester, MN | $4,009 | $0 |
| Raoul Concepcion, Md, MD | Urology | Nashville, TN | $3,974 | $0 |
| Gary Johnson, Md, MD | Family Medicine | Madison, WI | $3,964 | $0 |
| Jorg Dietrich, Md Phd, MD PHD | Neurology | Boston, MA | $3,958 | $0 |
| Dr. Fredrick May, Md, MD | Pediatrics | Indianapolis, IN | $3,691 | $0 |
| Prentiss Taylor, M.d, M.D | Internal Medicine | Chicago, IL | $3,682 | $0 |
| Carlton Barnswell, Md, MD | Urology | Elmont, NY | $3,649 | $0 |
| Dr. Steven Rowe, M.d., Ph.d, M.D., PH.D | Nuclear Radiology | Dallas, TX | $3,520 | $0 |
About Blue Earth Diagnostics Limited
Blue Earth Diagnostics Limited has made $27.3M in payments to 7,827 healthcare providers, recorded across 25,616 transactions in the CMS Open Payments database. In 2024, the company paid $2.7M. The top product by payment volume is Axumin ($13.1M).
Payments were distributed across 117 medical specialties. The top specialty by payment amount is Urology ($1.1M to 3,411 doctors).
Payment categories include: Food & Beverage ($590,630), Consulting ($2.3M), Research ($23.8M), Travel & Lodging ($137,657).
Blue Earth Diagnostics Limited is associated with 2 products in the CMS Open Payments database.